drugset / Trial / NCT05340829

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

NCT05340829

Phase 1 Unknown 18 enrolled He Huang
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label, phase I study to assess the safety and efficacy of ThisCART19A in patients with AIDS related B cell lymphoma/lympholeukemia.

Timeline

Start
2022-03-18
Primary completion
2024-03-30
Completion
2024-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ThisCART19A Cell therapy 2e+06 cells/kg
Subject ThisCART19A Cell therapy 3e+06 cells/kg
Subject ThisCART19A Cell therapy 4e+06 cells/kg

Indications